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Abstract
By meta-analyzing rare coding variants in whole-exome sequences of 4,133 schizophrenia cases 
and 9,274 controls, de novo mutations in 1,077 trios, and copy number variants from 6,882 cases 
and 11,255 controls, we show that individuals with schizophrenia carry a significant burden of rare 
damaging variants in 3,488 genes previously identified as having a near-complete depletion of 
loss-of-function variants. In schizophrenia patients who also have intellectual disability, this 
burden is concentrated in risk genes associated with neurodevelopmental disorders. After 
excluding known neurodevelopmental disorder risk genes, a significant rare variant burden persists 
in other loss-of-function intolerant genes, and while this effect is notably stronger in schizophrenia 
patients with intellectual disability, it is also seen in patients who do not have intellectual 
disability. Together, our results show that rare damaging variants contribute to the risk of 
schizophrenia both with and without intellectual disability, and support an overlap of genetic risk 
between schizophrenia and other neurodevelopmental disorders.
Introduction
Schizophrenia is a common and debilitating psychiatric illness characterized by positive 
symptoms (hallucinations, delusions, disorganized speech and behaviour), negative 
symptoms (social withdrawal and diminished emotional expression), and cognitive 
impairment that result in social and occupational dysfunction1,2. Operational diagnostic 
criteria for the disorder as described in the DSM-V require the presence of at least two of the 
core symptoms over a period of six months with at least one month of active symptoms3. It 
is increasingly recognized that current categorical psychiatric classifications have a number 
of shortcomings, in particular that they overlook the increasing evidence for etiological and 
mechanistic overlap between psychiatric disorders4.
A diverse range of pathophysiological processes may contribute to the clinical features of 
schizophrenia5. Indeed, previous studies have suggested a number of hypotheses about 
schizophrenia pathogenesis, including abnormal pre-synaptic dopaminergic activity6, 
postsynaptic mechanisms involved in synaptic plasticity7, dysregulation of synaptic 
pruning8, and disruption to early brain development9,10. This complexity is underpinned by 
the varied nature of genetic contributions to risk of schizophrenia. Genome-wide association 
studies have identified over 100 independent loci defined by common (minor allele 
frequency [MAF] > 1%) single nucleotide variants (SNVs)11, and a recent analysis 
determined that more than 71% of all one-megabase regions in the genome contain at least 
one common risk allele12. The modest effects of these variants (median odds ratio [OR] = 
1.08) combine to produce a polygenic contribution that explains only a fraction 
of the overall liability12. In addition, a number of rare variants have been identified that 
have far larger effects on individual risk. These are best exemplified by eleven large, rare 
recurrent copy number variants (CNVs) but evidence from whole-exome sequencing studies 
implies that many other rare coding SNVs and de novo mutations also confer substantial 
individual risk13–17. There is growing evidence that some of the same genes and pathways 
are affected by both common and rare variants7,18. Pathway analyses of common variants 
and hypothesis-driven gene set analyses of rare variants have begun to enumerate some of 
Singh et al. Page 2
Nat Genet. Author manuscript; available in PMC 2017 December 26.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
these specific biological processes, including histone methylation, transmission at 
glutamatergic synapses, calcium channel signaling, synaptic plasticity, and translational 
regulation by the fragile X mental retardation protein (FMRP)11,13,14,19,20.
In addition to exploring the biological mechanisms underlying schizophrenia, genetic 
analyses can also be used to understand its relationship to other neuropsychiatric and 
neurodevelopmental disorders. For instance, schizophrenia, bipolar disorder, and autism 
(ASD) show substantial sharing of common risk variants21,22. Sequencing studies of 
neurodevelopmental disorders suggest that this sharing of genetic risk may extend to rare 
variants of large effect. In the largest sequencing study of ASD to date, 20 of the 46 genes 
and all six CNVs implicated (false discovery rate [FDR] < 5%) had been previously 
described as dominant causes of developmental disorders23. Furthermore, an analysis of 
60,706 whole exomes led by the ExAC consortium identified 3,230 genes with near-
complete depletion of protein-truncating variants, and de novo loss-of-function (LoF) 
mutations identified in individuals with ASD or developmental disorders were concentrated 
in this set of “LoF intolerant” genes23–25. Similarly, evidence from rare variants for a 
broader shared genetic etiology between schizophrenia and neurodevelopmental disorders 
has begun to emerge. Analyses of whole-exome data provided support for an enrichment of 
schizophrenia rare variants in intellectual disability genes, and schizophrenia cases were also 
found to have a higher concentration of ultra-rare disruptive SNVs in the ExAC LoF 
intolerant genes compared to controls13,17,26.
However, the contribution of these rare variants to risk in the wider population of individuals 
diagnosed with schizophrenia, including those without intellectual disability, remains 
unclear. Intriguingly, the 11 rare CNVs found to be highly penetrant for schizophrenia also 
increased risk for intellectual disability and other congenital defects16,27, and more 
recently, a meta-analysis of whole-exome sequence data showed that LoF variants in 
SETD1A conferred substantial risk for both schizophrenia and neurodevelopmental 
disorders18. Concurrent analyses of autism whole-exome data found that de novo loss-of-
function (LoF) mutations identified in ASD probands, particularly those that disrupt genes 
associated with neurodevelopmental disorders, were disproportionately found in individuals 
with intellectual disability23,28. These emerging results raise the possibility that rare 
schizophrenia risk variants may be concentrated in a subset of schizophrenia patients with 
co-morbid intellectual disability. Here, we present the one of the largest accumulation of 
schizophrenia rare variant data to date, which we jointly analyze with phenotype data on 
cognitive function. Using this data set, we attempt to identify groups of genes disrupted by 
schizophrenia rare risk variants, and determine if a subset of patients disproportionately 
carry these damaging alleles.
Results
Study design
To maximize our power to detect enrichment of damaging variants in schizophrenia cases in 
groups of genes, we performed a meta-analysis of three different types of rare coding variant 
studies: (1) high-quality SNV calls from whole-exome sequences of 4,133 schizophrenia 
cases and 9,274 matched controls, (2) de novo mutations identified in 1,077 schizophrenia 
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parent-proband trios (Figure 1), and (3) CNV calls from genotyping array data of 6,882 
cases and 11,255 controls. The ascertainment of these samples, data production, and quality 
control were described previously18,29. All de novo mutations included in our analysis had 
been validated through Sanger sequencing, and stringent quality control steps were 
performed on the case-control data to ensure that sample ancestry and batch were closely 
matched between cases and controls (Online Methods).
For each data type, we used appropriate methods to test for an excess of rare variants (Figure 
1, Online Methods). In analyses of case-control SNV data, we applied an extension of the 
variant threshold burden test that corrected for exome-wide differences between cases and 
controls30. We tested all allele frequency thresholds below 0.1% observed in our data, and 
assessed statistical significance by permutation testing. In analyses of de novo SNV data, we 
compared the observed number of de novo mutations to random samples from an expected 
distribution based on a gene-specific mutation rate model to calculate an empirical P-value. 
For both types of whole-exome sequencing data, we restricted our analyses to loss-of-
function variants. Finally, in analyses of case-control CNV data, we used a logistic 
regression framework that compares the rate of CNVs overlapping a specific gene set while 
correcting for differences in CNV size and number of genes disrupted7,19,31. To ensure our 
model was well calibrated, we restricted our analyses to small deletions and duplications 
overlapping fewer than seven genes with MAF < 0.1% (Supplementary Figure 1, Online 
Methods).
We tested for an excess of rare damaging variants in schizophrenia patients in 1,766 gene 
sets (Online Methods, Supplementary Table 1, and detailed results below). Gene set P-values 
were computed using the three methods and variant definitions described above, and then 
meta-analyzed using Fisher’s Method to provide a single P-value for each gene set. Because 
we gave each data type equal weight, gene sets achieving significance typically show at least 
some signal in all three types of data. We observed a marked inflation in the quantile-
quantile (Q-Q) plot of gene set P-values (Supplementary Figure 2), so we conducted two 
analyses to ensure our results were robust and not biased due to methodological or technical 
artifacts. First, we observed no inflation of P-values when testing for enrichment of 
synonymous variants in our case-control and de novo analyses (Supplementary Figure 2). 
Second, we created random gene sets by sampling uniformly across the genome, and 
observed null distributions in Q-Q plots regardless of variant class and analytical method 
(Supplementary Figure 3). These findings suggested that our methods sufficiently corrected 
for known genome-wide differences in LoF and CNV burden between cases and controls, 
and other technical confounders like batch and ancestry.
Rare, damaging schizophrenia variants are concentrated in LoF intolerant genes
We first tested whether rare schizophrenia risk variants were consistently concentrated in 
genes defined loss-of-function intolerant across study design and variant type. Because some 
of our schizophrenia exome data was included in the ExAC database, we focused on the 
subset of 45,376 ExAC exomes without a known psychiatric diagnosis and that were not 
present in our study. From this subset, 3,488 genes were found to have near-complete 
depletion of such variants, which we defined as the LoF intolerant gene set. We found that 
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rare damaging variants in schizophrenia cases were enriched in LoF intolerant genes (P < 
3.6×10−10, Table 1, Figure 2), with support in case-control SNVs (P < 5×10−7; OR 1.24, 
1.16-1.31, 95% CI), case-control CNVs (P = 2.6×10−4; OR 1.21, 1.15 – 1.28, 95% CI), and 
de novo mutations (P = 6.7×10−3; OR 1.36, 1.1 – 1.68, 95% CI). While this result was 
consistent with observations in intellectual disability and ASD24,32 the absolute effect size 
is smaller (e.g. de novos, Supplementary Figure 4 and 5). We observed no excess burden of 
rare damaging variants in the remaining 14,753 genes (Figure 2, Supplementary Figure 5). 
Furthermore, this signal was spread among many different LoF intolerant genes: if we rank 
genes by decreasing significance, the enrichment disappears in the case-control SNV 
analysis (P > 0.05) only after the exclusion of the top 50 genes. This suggests that the 
contribution of damaging rare variants in schizophrenia is not concentrated in just a handful 
of genes, but instead spread across many genes.
Schizophrenia risk genes are shared with other neurodevelopmental disorders
Given the significant enrichment of rare damaging variants in LoF intolerant genes in 
developmental disorders, autism and schizophrenia, we next asked whether these variants 
affected the same genes. We found that autism risk genes identified from exome sequencing 
meta-analyses23 and genes in which LoF variants are known causes of severe developmental 
disorders as defined by the DDD study33,34 were significantly enriched for rare variants in 
individuals with schizophrenia (PASD = 9.5 ×10−6; PDD = 2.3 ×10−6; Table 1, Online 
Methods). Previous analyses have shown an enrichment of rare damaging variants in genes 
whose mRNA are bound by FMRP in both schizophrenia and autism35,13,32, so we sought 
to identify further shared biology by testing targets of neural regulatory genes previously 
implicated in autism32,36. We observed enrichment of both such sets: promoter targets of 
CHD8 (P = 1.1×10−6) and splice targets of RBFOX (P = 1.3×10−5) (Table 1). We noted that 
some published gene lists attributed to same biological process differed due to choices of 
assay, cell type, method of sample extraction, and threshold of statistical significance, 
leading to distinct results in our gene set analyses. For example, we observed a significant 
enrichment in the published FMRP binding gene set based on mouse brain data37, but with 
no signal in one based on a human kidney cell line38.
We also tested an additional 1,759 gene sets from databases of biological pathways with at 
least 100 genes, as we lacked power to detect weak enrichments in smaller sets (Online 
Methods). We observed enrichment of damaging rare variants in schizophrenia cases at FDR 
q < 0.05 in 35 of these gene sets (Supplementary Table 1, 2). These included previously 
implicated gene sets, like the NMDA receptor and ARC complexes13,14,35,37, as well as 
novel gene sets, such as genes involved in cytoskeleton (GO: 0007010), chromatin 
modification (GO:0016568), and chromatin organization (GO: 0006325). Furthermore, the 
gene sets most significantly enriched (FDR q < 0.01) for schizophrenia rare variants (Table 
1) had all been previously linked to autism, intellectual disability, and severe developmental 
disorders23,32,33. Our enrichment results matched some of the findings from a pathway 
analysis of common risk variants in psychiatric disorders, which also implicated neuronal 
and chromatin gene sets20. However, unlike that study, we found no enrichment of rare 
variants in immune-related gene sets.
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We noticed that the 1,759 gene sets we tested were collectively enriched with LoF intolerant 
genes when compared to a random sampling of genes from the genome (Supplementary 
Figure 6 and 7). For some of the gene sets associated with schizophrenia, this over-
representation was quite substantial: 67% of the gene targets of FMRP and 74% of the genes 
associated with severe neurodevelopmental disorders are LoF intolerant. To better 
understand the consequences of this overlap on our results, we extended the gene set 
enrichment methods (Online Methods) to condition on LoF intolerance and brain-expression 
for the 35 gene sets with FDR q < 0.05 in the previous analysis (Supplementary Table 2). We 
first observed that 22 of the 35 gene sets remained significant even after conditioning on 
brain expression (Supplementary Tables 3, Online Methods), suggesting they represent more 
specific biological processes involved in schizophrenia. However, only known autism risk 
genes (P = 4.4×10−4) and neurodevelopmental disorder genes (P = 3×10−5) had an excess of 
rare coding variants above the enrichment already observed in LoF intolerant genes 
(Supplementary Table 3). Thus, in addition to biological pathways implicated specifically in 
schizophrenia, at least a portion of the schizophrenia risk conferred by rare variants of large 
effect is shared with childhood onset disorders of neurodevelopment.
Schizophrenia patients with intellectual disability have a greater burden of rare damaging 
variants
In autism spectrum disorders, the observed excess of rare damaging variants has been shown 
to be greater in individuals with intellectual disability than those with normal levels of 
cognitive function28. We observed a similar phenomenon in schizophrenia cases carrying 
SETD1A LoF variants18, so next sought to explore whether this pattern is consistent in gene 
sets implicated in schizophrenia. We acquired relevant cognitive phenotype data for 2,971 of 
the 4,131 schizophrenia patients with whole-exome sequencing data (Supplementary Figure 
8). Of these individuals, 279 were clinically diagnosed with intellectual disability in addition 
to fulfilling the full diagnostic criteria for schizophrenia (SCZ-ID subgroup, Online 
Methods). We also identified 1,165 individuals for whom we could rule out cognitive 
impairment (by excluding pre-morbid IQ < 85, fewer than 12 years of schooling or lowest 
decile of composite cognitive measures, depending on available data, Online Methods). 
Finally, we identified 1,527 individuals who were not diagnosed with intellectual disability, 
but in whom some cognitive impairment could not be excluded.
When stratifying into these three groups (intellectual disability, no intellectual disability but 
cognitive impairment not excluded, no cognitive impairment), we observed that the burden 
of rare damaging variants in LoF intolerant genes was significantly greater in the SCZ-ID 
subgroup than in the remaining schizophrenia cases (P = 2.6×10−4; OR 1.3, 1.12– 1.51, 95% 
CI) or controls (P < 5×10−7; OR 1.61, 1.37 – 1.89, 95% CI; Figure 3). In the LoF intolerant 
gene set, 0.27 (0.2 – 0.35, 95% CI) extra singleton (defined as having an allele count of one 
in our data set) LoF variants were observed per exome in SCZ-ID cases compared to 
controls, while 0.10 (0.065 – 0.13, 95% CI) extra singleton LoF variants per exome were 
observed in the remaining schizophrenia cases compared to controls (Online Methods). 
Furthermore, SCZ-ID individuals had significant enrichment of rare LoF variants in 
developmental disorder genes compared to the other cases (P = 9×10−4; OR 2.36, 1.41– 
3.92, 95% CI) or to controls (P = 9.5×10−6; OR 3.43, 2.01– 5.86, 95% CI; Figure 4). 
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Compared to controls, the SCZ-ID individuals carried 0.045 (0.03 – 0.06, 95% CI) extra 
singleton LoF variants in developmental disorder genes per exome, suggesting that around 
4% of these cases had a LoF variant that is relevant to their clinical presentation. No 
enrichment in neurodevelopmental disorder genes was observed in schizophrenia patients 
without intellectual disability, suggesting that these genes were relevant only for that subset 
of schizophrenia patients (Figure 4, Supplementary Table 4). Notably, even after excluding 
known developmental disorder genes from the set of LoF intolerant genes, we still observed 
an enrichment of rare variants in SCZ-ID patients compared to the remaining cases (P = 
1×10−3; 1.26, 1.08 – 1.47, 95% CI) or to controls (P < 5×10−7; OR 1.54, 1.31– 1.81, 95% 
CI; Supplementary Figure 9). Rare variation in these genes contributes more to disease risk 
in the subset of patients with both schizophrenia and intellectual disability.
Rare variants confer risk for schizophrenia in individuals without intellectual disability
While rare damaging variants in LoF intolerant genes were most enriched in the subset of 
schizophrenia patients with intellectual disability, we still observed a weaker but significant 
enrichment in individuals with schizophrenia for whom we could confirm do not have 
intellectual disability (P = 5.5 × 10−4; 1.16, 1.05 – 1.27, 95% CI; Figure 3). Therefore, rare 
risk variants for schizophrenia follow the pattern previously described in autism: 
concentrated in individuals with intellectual disability, but not exclusive to that group. To 
produce a more accurate estimate of the effect of damaging rare variants on schizophrenia 
conditional on their effects on overall cognition, we recalculated the enrichment of rare 
variants in LoF intolerant genes in a subset of 2,161 schizophrenia cases and 2,398 controls 
for which data on years of education was available and for whom intellectual disability 
could be excluded (Supplementary Figure 8). After controlling for differences in educational 
attainment (Online Methods), individuals with schizophrenia have a 1.26-fold excess of rare 
variants in LoF intolerant genes (P = 2 × 10−6; 1.14 – 1.38, 95% CI). This increase in our 
observed odds ratio is consistent with previous accounts that rare damaging variants also 
affect educational attainment in controls39, thus biasing our unconditional estimate.
Discussion
Our integrated analysis of thousands of whole-exome sequences demonstrates that rare 
damaging variants increase risk of schizophrenia both with and without co-morbid 
intellectual disability. While the identification of individual genes remains difficult at current 
samples sizes, we show that the burden of damaging de novo mutations, rare SNVs and 
CNVs in schizophrenia is not scattered across the genome but is primarily concentrated in 
3,488 genes intolerant of loss-of-function variants. This observation is shared with autism, 
intellectual disability, and severe neurodevelopmental disorders32,40. We recapitulate 
enrichment in previously published gene sets, including transmission at glutamatergic 
synapses and translational regulation by FMRP, and implicate other gene sets previously 
linked to autism, intellectual disability, and severe developmental disorders. However, we 
find that all of these gene sets share a large number of underlying genes, and are especially 
enriched with the 3,488 genes intolerant of LoF variants. These overlaps among gene sets 
originating from very different analyses, as well as the subtleties of how they are defined, 
suggest caution in interpreting biological explanations from observed enrichments.
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We jointly analyzed the case-control SNV data with information on cognitive function for 
2,971 patients, and find that LoF variants disrupting genes associated with severe 
developmental disorders are disproportionately found in individuals with schizophrenia with 
co-morbid intellectual disability, with 4% of these cases having a single LoF variant that is 
relevant to their clinical presentation. Even after excluding variants in known developmental 
disorder genes, rare variants contribute a greater degree to schizophrenia risk in the SCZ-ID 
subgroup of patients than the remaining schizophrenia population. These results show that 
some of these genetic perturbations have clear manifestations in childhood, and that rare risk 
variants in schizophrenia are particularly associated with co-morbid intellectual disability. 
Our observations are consistent with results in autism in which rare risk variants are 
associated with intellectual disability22,23,28. Notably, a weaker but still significant rare 
variant burden was observed in schizophrenia patients without cognitive impairment, and 
this signal persists even after controlling for educational attainment. Together, these results 
demonstrate that rare variants have different contributions to schizophrenia risk depending 
on the degree of cognitive impairment. Importantly, they do not simply confer risk for a 
small subset of patients but contribute to disease pathogenesis more broadly.
Our study supports the observation that genetic risk factors for psychiatric and 
neurodevelopmental disorders do not follow clear diagnostic boundaries. Coding variants 
disrupting the same genes, and quite possibly, the same biological processes, increase risk 
for a range of phenotypic manifestation. This clinically variable presentation is reminiscent 
of LoF variants in SETD1A and 11 large copy number variant syndromes, previously shown 
to confer risk for schizophrenia in addition to other prominent developmental defects16,18. 
It is possible that these genes contain an allelic series of variants conferring gradations of 
risk. A recent schizophrenia GWAS meta-analysis demonstrated that the common variant 
association signal was similarly enriched in LoF intolerant genes41, suggesting that 
schizophrenia risk genes may be perturbed by common variants of subtle effects and 
disrupted by rare variants of high penetrance in the population. This possibility is also 
supported by the overlap in at least some of the pathways affected by both rare and common 
variation, such as chromatin remodeling. However, the most common deletion in the 
22q11.2 locus and a recurrent two base deletion in SETD1A are associated with both 
schizophrenia and more severe neurodevelopmental disorders, suggesting the same variants 
can also confer risk for a range of clinical features18,42,43. Ultimately, it may prove 
difficult to clearly partition patients genetically into subtypes with similar clinical features, 
especially if genes and variants previously thought to cause well-characterized Mendelian 
disorders can have such varied outcomes. This pattern is consistent with the hypothesis that 
LoF variants in genes under genic constraint result in a spectrum of neurodevelopmental 
outcomes with the burden of mutations highest in intellectual disability and least in 
schizophrenia, corresponding to a gradient of neurodevelopmental pathology indexed by the 
degree of cognitive impairment, age of onset, and severity4.
Despite the complex nature of genetic contributions to risk of schizophrenia, it is notable 
that across study design (trio or case-control) and variant class (SNVs or CNVs), risk loci of 
large effect are concentrated in a small subset of genes. Previous rare variant analyses in 
other neurodevelopmental disorders, such as autism, have successfully integrated 
information across de novo SNVs and CNVs to identify novel risk loci23. As sample sizes 
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increase, meta-analyses leveraging the shared genetic risk across study designs and variant 
types, including those we did not consider here, such as classical recessive inheritance, will 
be similarly well powered to identify additional risk genes in schizophrenia.
Online Methods
Sample collections
The ascertainment, data production, and quality control of the schizophrenia case-control 
whole-exome sequencing data set had been described in detail in an earlier publication18. 
Briefly, the data set was composed of schizophrenia cases recruited as part of eight 
collections in the UK10K sequencing project, and matched population controls from non-
psychiatric arms of the UK10K project, healthy blood donors from the INTERVAL project, 
and five Finnish population studies. The UK10K data set was combined and analyzed with 
published data from a Swedish schizophrenia case-control study35. The data production, 
quality control, and analysis of the case-control CNV data set was described in an earlier 
publication29. The schizophrenia cases were recruited as part of the CLOZUK and 
CardiffCOGS studies, which consisted of both schizophrenia individuals taking the 
antipsychotic clozapine and a general sample of cases from the UK. Matched controls were 
selected from four publicly available non-psychiatric data sets. All samples were genotyped 
using Illumina arrays, and processed and called under the same protocol. Sanger-validated 
de novo mutations identified through whole exome-sequencing in seven published studies of 
schizophrenia parent-proband trios were aggregated and re-annotated for enrichment 
analyses13,44–49. A full description of each trio study, including sequencing and capture 
technology and sample recruitment was previously described18.
Sample and variant quality control
We jointly called each case data set with its nationality-matched controls, and excluded 
samples based on contamination, coverage, non-European ancestry, and excess 
relatedness18. A number of empirically derived filters were applied at the variant and 
genotype level, including filters on GATK VQSR, genotype quality, read depth, allele 
balance, missingness, and Hardy-Weinberg disequilibrium18. After variant filtering, the per-
sample transition-to-transversion ratio was ~3.2 across the entire data set, as expected for 
populations of European ancestry50. For the case-control CNV analysis, we similarly 
excluded samples based on excess relatedness, and only CNVs supported by more than 10 
probes and greater than 10 kilobases in size were retained to ensure high quality calls. All de 
novo mutations in our study had been validated using Sanger sequencing.
We used the Ensembl Variant Effect Predictor (VEP) version 75 to annotate all variants 
(SNVs and CNVs) according to Gencode v.19 coding transcripts. We defined frameshift, 
stop gained, splice acceptor, and donor variants as loss-of-function (LoF), and missense or 
initiator codon variants with the recommended CADD Phred score cut-off of greater than 15 
as damaging missense51. A gene was annotated as disrupted by a deletion if part of its 
coding sequence overlapped the copy number event. We more conservatively defined genes 
as duplicated only if the entire canonical transcript of the gene overlapped with the 
duplication event.
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Statistical tests of the case-control exome data used case-control permutations within each 
population (UK, Finnish, Swedish) to generate empirical P-values to test hypotheses. No 
genome-wide inflation was observed in burden tests of individual genes18. In the curated set 
of de novo mutations, we observed the expected exome-wide number of synonymous 
mutations given gene mutation rates from previously validated models24, suggesting variant 
calling was generally unbiased across Gencode v.19 coding genes. Lastly, the case-control 
CNV data set had been previously analyzed for burden of CNVs affecting individual genes, 
and enrichment analyses in targeted gene sets7,29.
Rare variant gene set enrichment analyses
Case-control enrichment burden tests—For the case-control SNV data set, we 
performed permutation-based gene set enrichment tests using an extension of the variant 
threshold method30. This method assumed that variants with a MAF below an unknown 
threshold T were more likely to be damaging than variants with a MAF above T, and this 
threshold was allowed to differ for every gene or pathway tested. To consider different 
possible values for threshold T, a gene or gene set test statistic t(T) was calculated for every 
allowable T, and the maximum test-statistic, or tmax, was selected. The statistical 
significance of tmax was evaluated by permuting phenotypic labels, and calculating tmax from 
the permuted data such that different values of T could be selected following each 
permutation. In Price et al., t(T) was defined as the z-score calculated from regressing the 
phenotype on the sum of the allele counts of variants in a gene with MAF < T. We extended 
this method to test for enrichment in gene sets by regressing schizophrenia status on the total 
number of damaging alleles in the gene set of interest with MAF < T (Xin,T) while 
correcting for the total number of damaging alleles genome-wide with MAF < T (Xall,T). 
Xin,T controlled for exome-wide differences between schizophrenia cases and controls, 
ensuring any significant gene set result was significant beyond baseline differences. t(T) was 
defined as the t-statistic testing if the regression coefficient of Xin,T deviated from 0. We 
then calculated t(T) for all observed thresholds below a minor allele frequency of 0.1%, and 
selected the maximum value for the tmax based on the observed data. To calculate a null 
distribution for tmax, we performed two million case-control permutations within each 
population (UK, Finnish, and Swedish) to control for batch and ancestry, and calculated tmax 
for each permuted sample while allowing T to vary. The P-value for each gene set was 
calculated as the fraction of the two million permuted samples that had a greater tmax than 
what was observed in the unpermuted data. The odds ratio and 95% confidence interval of 
each gene set was calculated using a logistic regression model, regressing schizophrenia 
status on Xin while controlling for total number of variants genome-wide (Xall) and 
population (UK, Finnish, and Swedish). Unlike gene set P-values which were calculated 
using permutation across multiple frequency thresholds, the odds ratios an d 95% CI were 
calculated using only variants observed once in our data set (allele count of 1) to ensure they 
were comparable between tested gene sets.
CNV logistic regression—We adapted a logistic regression framework described in 
Raychaudhuri et al. and implemented in PLINK to compare the case-control differences in 
the rate of CNVs overlapping a specific gene set while correcting for differences in CNV 
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size and total genes disrupted7,19,31. We first restricted our analyses to coding deletions and 
duplications, and tested for enrichment using the following model:
where for individual i, pi is the probability they have schizophrenia i, si is the total length of 
CNVs, gall is the total number of genes overlapping CNVs, and gin is the number of genes 
within the gene set of interest overlapping CNVs. It has been shown that β1 and β2 
sufficiently controlled for the genome-wide differences in the rate and size of CNVs 
between cases and control, while β3 captured the true gene set enrichment above this 
background rate7,19,31. For each gene set, we reported the one-sided P-value, odds ratio, 
and 95% confidence interval of β3.
Weighted permutation-based sampling of de novo mutations—For each variant 
class of interest, we first determined the total number of de novo mutations observed in the 
1,077 schizophrenia trios. We then generated 2 million random samples with the same 
number of de novo mutations, weighting the probability of observing a mutation in a gene 
by its estimated mutation rate. The baseline gene-specific mutation rates were obtained 
using the method described in Samocha et al. and adapted to produce LoF and damaging 
missense rates for each Gencode v.19 gene. These mutation rates adjusted for both sequence 
context and gene length, and were successfully applied in the primary analyses of large-scale 
exome sequencing of autism and severe developmental disorders with replicable 
results23,32,40. For each gene set, one-sided enrichment P-values were calculated as the 
fraction of two million random samples that had a greater or equal number of de novo 
mutations in the gene set of interest than what is observed in the 1,077 trios. The effect size 
of the enrichment was calculated as the ratio between the number of observed mutations in 
the gene set of interest and the average number of mutations in the gene set across the two 
million random samples. We adapted a method in Fromer et al. to calculate 95% credible 
intervals for the enrichment statistic13. We first generated a list of one thousand evenly 
spaced values between 0 and ten times the point estimate of the enrichment. For each value, 
the mutation rates of genes in the gene set of interest were multiplied by that amount, and 
50,000 random samples of de novo mutations were generated using these weighted rates. 
The probability of observing the number of mutations in the gene set of interest given each 
effect size multiplier was calculated as the fraction of samples in which the number of 
mutations in the gene set is the same as the observed number in the 1,077 trios. We 
normalized the probabilities across the 1,000 values to generate a posterior distribution of 
the effect size, and calculated the 95% credible interval using this empirical distribution.
Combined joint analysis—Gene set P-values calculated using the case-control SNV, 
case-control CNV, and de novo data were meta-analyzed using Fisher’s combined 
probability method with df = 6 to provide a single test statistic for each gene set. We 
corrected for the number of gene sets tested in the discovery analysis (n = 1,776) by 
controlling the false discovery rate (FDR) using the Benjamini-Hochberg approach, and 
reported only results with a q-value of less than 5%.
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Description of gene sets
The full list of tested gene sets is found in Supplementary Table 1, and a detailed description 
is provided in the Supplementary Note. Briefly, we tested all gene sets with more than 100 
genes from five public pathway databases. We additionally tested additional gene sets 
selected based on biological hypotheses about schizophrenia risk, and genome-wide screens 
investigating rare variants in intellectual disability, autism spectrum disorders, and other 
neurodevelopmental disorders. All gene identifiers were mapped to the GENCODE v.19 
release, and all non-coding genes were excluded. A total of 1,766 gene sets were included in 
our analysis.
Selection of allele frequency thresholds and consequence severity
For the case-control whole-exome data, we applied an extension of the variant threshold 
model (described above). With this method, we tested damaging variants at a number of 
frequency thresholds without specifying an a priori MAF cut-off. All thresholds below a 
MAF of 0.1% observed in our data were tested, and we assessed statistical significance by 
permutation testing. For all the whole-exome data (case-control and trio data), we restricted 
our analyses to loss-of-function variants. These variants have a clear and severe predicted 
functional consequence in that they putatively cause a single-copy loss of a gene. 
Furthermore, this class of variants had been demonstrated to have the strongest genome-
wide enrichment between cases and controls across neurodevelopmental and psychiatric 
disorders18,32,40. When selecting MAF cut-offs for case-control CNVs, we found that 
while the bulk of the test statistics were not inflated, the tail of gene set P-values were 
dramatically inflated even when testing for enrichment in the random gene sets 
(Supplementary Figure 1). This inflation in the tail of the Q-Q plot was driven in part by 
very large (overlapping more than 10 genes), more common (MAF between 0.1% and 1%) 
CNVs observed mainly in cases or controls. Some of these, such as the known syndromic 
CNVs, likely harbored true risk genes. However, because these CNVs were highly recurrent 
in cases and depleted in controls, and disrupted a large number of genes, any gene set that 
included even a single gene within these CNVs would appear to be significant, even after 
controlling for total CNV length and genes overlapped. To ensure our model was well 
calibrated and its P-values followed a null distribution for random gene sets, we explored 
different frequency and size thresholds, and conservatively restricted our analysis to copy 
number events overlapping less than seven genes (excluding the largest 10% of CNVs) with 
MAF < 0.1% (Supplementary Figure 1). Our main conclusions remained unchanged even if 
we selected a more stringent (excluding the largest 15% of CNVs) or less stringent 
(excluding the largest 5% of CNVs) size threshold.
Robustness of enrichment analyses
We uniformly sampled genes from the genome (as defined by Gencode v.19) to generate 
random gene sets with the same size distribution as the 1,776 gene sets in our discovery 
analysis. For each random set, we calculated gene set P-values for the case-control SNV 
data, case-control CNV data, and de novo data using the appropriate method and frequency 
cut-offs across all variant classes. A Q-Q plot was generated using P-values from enrichment 
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tests of each data set and variant type. Reassuringly, we observed null distributions in all 
such Q-Q plots (Supplementary Figure 3).
Comparison of de novo enrichment with broader neurodevelopmental disorders
We aggregated and re-annotated de novo mutations from four studies: 1,113 severe DD 
probands40, 4,038 ASD probands23,32, and 2,134 control probands28,32. We used the 
Poisson exact test to calculate differences in de novo rates in constrained genes between 
schizophrenia, ASD, and DD and controls. Counts in each functional class (synonymous, 
missense, damaging missense, and LoF) were tested separately, and the one-sided P-value, 
rate ratio, and 95% CI of each comparison were reported and plotted in Figure 2, 
Supplementary Figure 4 and 5.
Conditional analyses
In each of the three methods we used for gene set enrichment, we restricted all variants 
analyzed to those that reside in the background gene list, and tested for an excess of rare 
variants in genes shared between the gene set of interest (K) and the background list (B). 
Brain-enriched genes from GTEx, and the ExAC LoF intolerant genes (pLI > 0.9) were used 
as backgrounds (see above). For the case-control SNV data, we modified the variant 
threshold method to regress schizophrenia status on the total number of damaging alleles in 
genes present in both the gene set of interest and the background gene set (K ∩ B), while 
correcting for the total number of damaging alleles in the set of all background genes (B). 
The logistic regression model for the case-control CNV data was modified to:
where gB is the total number of background genes overlapping a CNV, and gK ∩ B is the 
number of genes in the intersection of the gene set of interest and the background list 
overlapping a CNV. Finally, we determined the total number of de novo mutations within the 
background gene list observed in the 1,077 schizophrenia trios, and generated 2 million 
random samples with the same number of de novo mutations. For each gene set, one-sided 
enrichment P-values were calculated as the fraction of two million random samples that had 
a greater or equal number of de novo mutations in genes in K ∩ B than what is observed in 
the 1,077 trios. Gene set P-values were combined using Fisher’s method. We restricted our 
conditional enrichment analysis to gene sets with q-value < 5% in the discovery analysis, 
and adjusted for multiple testing using Bonferroni correction (P = 0.00071, or 0.05/67 tests; 
see Supplementary Table 3).
Rare variants and cognition in schizophrenia
Within the UK10K study, 97 individuals from the MUIR collection were given discharge 
diagnoses of mild learning disability and schizophrenia (ICD-8 and -9). The recruitment 
guidelines of the MUIR collection were described in detail in a previous publication52. In 
brief, evidence of remedial education was a prerequisite to inclusion, and individuals with 
pre-morbid IQs below 50 or above 70, severe learning disabilities, or were unable to give 
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consent were excluded. The Schizophrenia and Affective Disorders Schedule-Lifetime 
version (SADS-L) in people with mild learning disability, PANSS, RDC, and DSM-III-R, 
and St. Louis Criterion were applied to all individuals to ensure that any diagnosis of 
schizophrenia was robust. Using the clinical information provided alongside the Swedish 
and Finnish case-control data sets, we identified additional 182 schizophrenia individuals 
who were similarly diagnosed with intellectual disability, for a total of 279 individuals.
Cognitive testing and educational attainment data available for a subset of samples were 
used identify schizophrenia individuals without cognitive impairment. For 502 individuals 
from the Cardiff collection in the UK10K study, we acquired their pre-morbid IQ as 
extrapolated from National Adult Reading Test (NART), and identified 412 individuals for 
analysis after excluding all individuals with predicted pre-morbid IQ of less than 85 (or 
below one standard deviation of the population distribution for IQ). We additionally 
acquired information on educational attainment in 54 schizophrenia individuals in the 
UK10K London collection, and retained 27 individuals without intellectual disability and 
who completed at least 12 years of schooling. Lastly, the California Verbal Learning Test 
was conducted on 124 Finnish schizophrenia individuals sequenced as part of UK10K, and a 
composite score was generated from measures of verbal and visual working memory, verbal 
abilities, visuoconstructive abilities, and processing speed. All individuals with intellectual 
disability had been excluded from cognitive testing. Within this set of samples, we 
additionally excluded any individuals who ranked in the lowest decile in CVLT composite 
score, and retained 92 individuals for analysis. According to these criteria, we identified 531 
of 697 schizophrenia individuals from the UK and Finnish data sets with cognitive data as 
not having intellectual disability. We additionally acquired data on educational attainment 
for the Swedish schizophrenia cases and controls from the Swedish National Registry. After 
excluding individuals with intellectual disability, we identified 1,527 schizophrenia 
individuals who did not complete secondary school (less than 12 years of schooling), and 
634 schizophrenia individuals who completed at least compulsory and upper secondary 
schooling (at least 12 years of schooling). The last group with the greatest educational 
attainment and without intellectual disability was defined as cases without cognitive 
impairment. In the Swedish sample, 49.4% of control samples had lower educational 
attainment than the 634 individuals with schizophrenia defined as having no cognitive 
impairment, suggesting that our definition was sufficiently strict. In total, combining the 
UK, Finnish, and Swedish data, we identified 1,165 schizophrenia individuals without 
cognitive impairment.
Using the variant threshold method, we tested for differences in rare LoF burden between 
the three case groups (intellectual disability, did not complete secondary school, no cognitive 
impairment) against controls. We restricted these analyses to three gene sets (LoF intolerant 
genes, genes in which LoF variants are diagnostic for severe developmental disorders, and 
LoF intolerant genes after excluding severe developmental disorders genes), and adjusted for 
multiple testing using Bonferroni correction (P = 0.0038, or 0.05/13 tests). Supplementary 
Table 4 enumerated all the statistical tests performed. To estimate the per-exome excess of 
rare singleton (defined as having an allele count of one in our data set) LoF variants in cases 
compared to controls, we regressed Xin (the number of LoF variants in the gene set of 
interest) on case status (0 or 1) while controlling for Xall (the total number of LoF variants 
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genome-wide) and population (UK, Finnish, and Swedish). The effect size and 95% CI of 
the regression coefficient of case status predictor were reported.
Data Availability
Sequence data and processed VCFs for the UK10K project were deposited into the European 
Genome-phenome Archive (EGA) under study accession code EGAO00000000079. The 
processed VCFs from the Swedish case-control study were deposited in dbGAP under 
accession code (phs000473.v1.p1). Rare variant counts, and gene-level association results 
from combining the whole-exome sequencing data sets were described in a previous 
publication18 and were made available on the PGC results and download page (https://
www.med.unc.edu/pgc/results-and-downloads).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Analysis workflow. Data sets are shown in blue, statistical methods and analysis steps are 
shown in green, and results (figures and tables) from the analysis are shown in orange. A: 
Enrichment analyses in 1,766 gene sets using the entire rare variant data set. B: Enrichment 
analyses in LoF intolerant and developmental disorder genes in the subset of cases with 
information on cognitive function. ID: intellectual disability; SCZ: schizophrenia; SCZ-ID: 
schizophrenia patients with intellectual disability.
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Figure 2. 
Enrichment of schizophrenia rare variants in genes intolerant of loss-of-function variants. A: 
Schizophrenia cases compared to controls for rare SNVs and indels; B: Rates of de novo 
mutations in schizophrenia probands compared to control probands; C: Case-control CNVs. 
P-values shown were from the test of LoF enrichment in A, LoF enrichment in B, and all 
CNVs enrichment in C. Error bars represent the 95% CI of the point estimate. LoF 
intolerant: 3,448 genes with near-complete depletion of truncating variants in the ExAC 
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database; Rest: the remaining genes in the genome with pLI < 0.9; Damaging missense: 
missense variants with CADD phred > 15. Asterisk: P < 1 x 10-3.
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Figure 3. 
Enrichment of rare loss-of-function variants in LoF intolerant genes in schizophrenia cases 
stratified by information on cognitive function compared to controls. The P-values shown 
were calculated using the variant threshold method comparing LoF burden between the 
corresponding cases and controls. Error bars represent the 95% CI of the point estimate. 
Damaging missense: missense variants with CADD phred > 15.
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Figure 4. 
Enrichment of rare loss-of-function variants in known severe developmental disorder genes 
in schizophrenia cases stratified by information on cognitive function compared to controls. 
The P-values shown were calculated using the variant threshold method comparing LoF 
burden between the corresponding cases and controls. Error bars represent the 95% CI of the 
point estimate. Damaging missense: missense variants with CADD phred > 15.
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